Form 4 for NBIX NEUROCRINE BIOSCIENCES INC
Accepted 2024-02-14 00:00:00 ET · period of report 2024-02-13 · accession 0000914475-24-000056 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-02-14 | 2024-02-13 | NBIX | GORMAN KEVIN CHARLES | CEO, Dir | M - OptEx | $39.28 | +5,090 | 512.1K | +1% | +$200.0K |
| DM | 2024-02-14 | 2024-02-13 | NBIX | GORMAN KEVIN CHARLES | CEO, Dir | M - OptEx | $39.28 | -5,090 | 0 | -100% | -$200.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-13 | M | A | 2,778 | $35.99 | 509,740 | D | — | — | (F1) This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock. |
| 2 | Common | Common Stock | 2024-02-13 | M | A | 2,312 | $43.24 | 512,052 | D | — | — | (F1) This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock. (F2) 491,365 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power. |
| 3 | Derivative | Incentive Stock Option | 2024-02-13 | M | D | 2,778 | $35.99 | 0 | D | $35.99 · — to 2026-02-05 | 2,778 Common Stock | (F3) The option was granted February 5, 2016 and vested in 48 equal monthly installments beginning March 5, 2016. |
| 4 | Derivative | Incentive Stock Option | 2024-02-13 | M | D | 2,312 | $43.24 | 0 | D | $43.24 · — to 2027-02-06 | 2,312 Common Stock | (F4) The option was granted February 6, 2017 and vested in 48 equal monthly installments beginning March 6, 2017. |